Sirona Biochem: Interview with Chief Scientific Officer Dr. Deliencourt-Godefroy on the Development Pipeline
Canada NewsWire
VANCOUVER, April 14, 2020
VANCOUVER, April 14, 2020 /CNW/ – Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) (“Sirona“) is pleased to inform its shareholders that a video interview with its Chief Scientific Officer, Dr. Géraldine Deliencourt-Godefroy, has been published by Austrian journalist Joachim Brunner (www.smallcapinvestor.de).
Here is a short sneak preview in the following Q&A format:
Q. What makes your (technology) platform so unique?
Q: What is your (development) focus now?
A. So, we have the anti-wrinkle (compound). It is working well. We have made some good advance…
Q: What is the next big thing for you?
The interview can be viewed at www.youtu.be/vDLtSUR2OC8 or on Sirona’s website www.sironabiochem.com.
On another note, Sirona will be attending the 2020 BIO International Convention, June 8-12, 2020. The conference will be held virtually and will allow Sirona to present its technology to key pharmaceutical companies. Virtual BIO One-on-One Partnering meetings will also take place. Sirona is adapting to industry changes driven by the evolving impact of COVID-19. These changes have been seamless for the team and in many cases have improved the ability to operate globally.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona’s subsidiary lab, TFChem, specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments.
For more information, please visitwww.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
______________________________
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
SOURCE Sirona Biochem Corp.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/April2020/14/c2071.html
Contact:
For more information regarding this press release, please contact: Investor Enquiries: Jonathan Williams, Managing Director, Momentum PR, Phone: 1.450.332.6939, Email: jwilliams@momentumpr.com; Corporate Enquiries: Dr. Howard Verrico, CEO, Chairman of the Board, Sirona Biochem Corp., Phone: 1.604.641.4466, Email: info@sironabiochem.com
© 2020 Canjex Publishing Ltd. All rights reserved.
- Published in Bio technology, News Home, Sirona Biochem
SIRONA BIOCHEM INITIATES COVID-19 AND INFECTIOUS DISEASES DEVELOPMENT PROGRAM
Sirona Biochem Corp.’s French subsidiary lab, TFChem, has initiated an anti-viral program to produce potential new anti-viral agents to assist in combating COVID-19 and other infectious diseases.
After two months of extensive research, TFChem scientists have determined the proprietary platform technology can be applied to develop new antiviral compounds. Work on this program has begun with a goal to produce new therapies in three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. These categories are all Glycosides with a carbohydrate core and therefore suitable for application of the technology. The goal is to develop novel multi-target antiviral compounds, affecting different steps of the viral life cycle. The company believes there is a high therapeutic potential for these Glycosides.
Viruses are a leading cause of death globally. Therapies to treat most viral infections are limited and the emergence of new viruses can greatly endanger society, as is currently the case with the pandemic caused by COVID-19, also known as Coronavirus or SARS-CoV-2. There is a need to identify novel, effective and safe drugs to treat viral infections. Awareness of the value of this project and other antiviral projects ongoing globally has become apparent.
“We have the financial resources to initiate this project and anticipate we will secure further non-dilutive financing to support the project ongoing. We are working to secure new senior laboratory technicians to join our current team at TFChem and have identified suitable candidates within France that will greatly expand our capabilities. We will also reach out to our current partners to explore how their capabilities can assist us in this project. None of these efforts will affect our current core projects which are principally managed by different team members than are involved in early stage compound synthesis,” said Dr. Howard Verrico, CEO of Sirona Biochem.
“These are difficult times with our global battle against COVID-19. We are receiving tremendous support from the French government and have a dedicated team who are always searching for new opportunities to apply our technology. Dr. Geraldine Deliencourt-Godefroy, our Chief Scientific Officer, has a proven ability to identify projects with significant probabilities of clinical success. On her recommendation and the recognition to potentially deliver novel therapies that can benefit the global population, we have decided to proceed with this program,” Dr. Verrico added.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona’s subsidiary lab, TFChem, specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
We seek Safe Harbor.
- Published in Bio technology, News Home, Sirona Biochem
Sirona Biochem Announces SGLT2 Inhibitor Development Progress
Momentum Public Relations
Press Release: July 3, 2019
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (“Sirona“) is pleased to announce that clinical development of Sirona’s SGLT2 inhibitor, TFC-039, which is currently well into phase 1 of human trials, is progressing on schedule with no adverse events.
Wanbang and Sirona are unable to comment further on the details of the progress for strategic as well as competitive reasons.
Sirona Biochem’s SGLT2 inhibitor, TFC-039, was licensed to Wanbang Biopharmaceuticals, a wholly owned subsidiary of Shanghai Fosun Pharmaceutical Group in 2014 with exclusive rights for China. In exchange for this license, Wanbang Biopharma will provide upfront and milestone payments of up to US$9.5M in addition to royalty payments for product sales in China. Since the initial licensing agreement, the Fosun Pharma group has invested tremendous resources to the development and has already paid Sirona $1.5US Million in milestone payments. Wanbang Biopharmaceuticals has approved this news release.
“Wanbang continues to be very dedicated to the development of this treatment for diabetes. The current status of the program is exactly where we expected it to be at this time and while we would like to comment further, we understand and respect the need for confidentiality”, said Dr. Howard Verrico, CEO of Sirona Biochem. “Our business development and legal teams have been committed to working on the ground in China to maintain and strengthen the relationship with the two companies. We anticipate that the mutual benefits will extend well beyond this program and into other regions in the near future. Having two projects based on Sirona’s technology reach clinical trials is a rare achievement for a biotechnology company of our size.”
Worldwide, an estimated 8.5% of the adult population (422 million people) have type 2 diabetes, and about a quarter of them (148 million; 10.9% of the population) live in China. A recent study in Chinaanalyzed data from more than 400,000 adults suffering from type 2 diabetes. It was revealed that men and women with type 2 diabetes had a 32% and 64% greater risk of developing cancer, respectively, compared with their peers in the general population. Cancer is a leading cause of death in China.
Source: www.medscape.com/viewarticle/912934
About Wanbang Biopharmaceuticals and Fosun Pharmaceuticals
Wanbang Biopharmaceuticals develops, manufactures and sells drugs with indications for chronic disease treatment, antibiotics, and other endocrine diseases in China. Founded in 1981, they are presently headquartered in Xuzhou, China, and are a subsidiary of Shanghai Fosun Pharmaceutical Group. Fosun is a leader in the pharmaceutical industry and regarded as one of the top five domestic pharmaceutical companies in China. For more information on Fosun and Wanbang, please visit www.fosunpharma.com/en.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
SOURCE Sirona Biochem Corp.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/July2019/03/c3219.html
Contact:
regarding this press release, please contact: Jonathan Williams, Managing Director, Momentum PR, Phone: 1.450.332.6939, Email: jwilliams@momentumpr.com
- Published in Bio technology, Life Sciences, News Home, Sirona Biochem, Skin Care
Sirona Biochem Billion Dollar Skin Lightening Opportunity With TFC-1067 Compound
Sirona Biochem is the center of attention on signing a landmark licensing deal for its proprietary skin-lightening compound with a company topping billions of dollars in sales. The signing of the deal comes at a time of growing demand for skin lightening products with the market poised to reach $20 billion by 2022.
Sirona | Rodan + Field Deal
The cosmetic ingredient and drug discovery company remain well positioned to generate significant value on the burgeoning skin lightening market. Backed by a proprietary platform technology that has already given rise to TFC-1067, the company is already eliciting strong interest from some of the biggest skin care brands.
The signing of a term sheet with Rodan + Fields LLC for proprietary TFC-1067 compound might as well have opened the door for the company to generate significant value going forward. Under the terms of the agreement, Sirona Biochem is to manufacture and supply TFC-1067 for use by Rodan + Fields in its products.
The company stands to generate significant revenues on the sale of the skin-lightening compound. In addition, it is entitled to a fee by Rodan + Fields on the signing of the definitive agreement. The company will also earn milestone fees on each product that Rodan + Fields sales, utilizing the skin-lightening agent TFC-1067. The two have also agreed to establish regular formal meetings to explore future opportunities.
A partnership with Rodan + Fields marks an important milestone as Sirona Biochem seeks to generate significant value from its proprietary skin lighting compound. Skincare brand Rodan + Fields has generated more than $1 billion in sales since 2016, seen as an ideal partner for Sirona after years of TFC-1067 R&D investments.
The compound stands out in part because it is superior to current actives in the market in addition to being safe and free of hydroquinone. TFC-1067 has also proved to be superior in the treatment of dyschromia with no adverse effects.
The use of TFC-1067 in Rodan + Fields products opens the door for Sirona Biochem to recoup a substantial amount of money spent on the development of the skin lighting agent.
“After many years of developing TFC-1067 with the support of the French government and European Union in the Cosmetic Valley, France, we are excited to partner with skincare industry leader Rodan + Fields. This marks an important milestone for Sirona Biochem,” explained Dr. Howard Verrico CEO of Sirona Biochem.
Skin Lightening Opportunity
Sirona Biochem is on the cusp of something great in the skin care market. The company has already secured a U.S patent for the flagship skin-lightening agent TFC-1067 further strengthening its IP portfolio. The new patent adds to similar patents granted in Germany, France, and the United Kingdom.
With the patent, the company can now pursue licensing deals similar to the one signed with Rodan + Fields. Such deals should go a long way in helping the company strengthen its revenue streams through licensing fees as well as milestone fees and royalty payments.
Sirona Biochem is currently in advanced negotiations in North America and Asia as it eyes licensing deals for the skin-lightening compound. Given the potential impact of TFC-1067 in the multi-billion dollar skin lightening market, the company could be a potential acquisition target for big companies wishing to own TFC-1067 outright.
- Published in Bio technology, Dermatology, Sirona Biochem, Skin Care
Sirona Biochem Hires Contract Research Organization for Manufacturing Process Optimization for TFC-1067
Momentum Public Relations
Press Release: May 22, 2019
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (“Sirona“) is pleased to announce it has commissioned Contract Research Organization (CRO) Roowin (www.roowin.com) to develop the final chemical process required for large scale manufacturing of TFC-1067. This is another important step in the commercialization of Sirona’s novel skin lightening agent.
Sirona anticipates the need for multiple kilogram production of TFC-1067 in the short term and is therefore taking this necessary intermediate step. Sirona will then proceed to manufacture an inventory of TFC-1067 of up to 20 kilograms to be ready for anticipated orders. Due to the high potency of the compound, each kilogram will supply Sirona’s active skin lightening ingredient to produce ten thousand consumer size (fifty milliliters) containers of finished product.
“The chemistry of TFChem (Sirona’s subsidiary) is unique and our science team has an excellent understanding of this chemistry. We have already successfully worked on production of TFC-1067 at the kilogram scale,” reports Patrice Rool, CEO of Roowin. “Our scientists will collaborate with TFChem to develop the most efficient final process to manufacture TFC-1067. We are very excited to be a part of the ongoing development of this innovative skin lightener.”
“Roowin’s expertise in manufacturing process development will move TFC-1067 closer to final commercialization. In addition, our scientists at TFChem have developed new chemistry that will further improve manufacturing efficiencies and lower cost of goods,” Dr. Verrico concluded. “The new manufacturing process for TFC-1067 we anticipate will be used at manufacturing sites globally down the road. Roowin has extensive experience with our chemistry and we are excited to be working together again.”
About Roowin
Roowin is a privately-owned Contract Research Organization (CRO) headquartered in Riom (Auvergne), France. Its core business being in high value-added fine chemistry, Roowin offers a large range of chemical services. Roowin supports customers and partners to advance their drug candidates from early research phase up to licensing out API in phase II or to the Market for small batches, about 20 kilograms.
Roowin is accredited ISO 9001. Roowin’s facilities include cGMP facilities: Kilo-laboratory / Pilot plant. Roowin can accompany its customers from early lead optimization through scale-up and small-scale GMP synthesis up to medium scale GMP manufacturing.
For more information, please visit www.roowin.com.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
SOURCE Sirona Biochem Corp.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/May2019/22/c5079.htmlv
- Published in Bio technology, Life Sciences, News Home, Sirona Biochem
Sirona Biochem Announces Resignation of Board Director
Momentum Public Relations
Press Release: October 27, 2017
VANCOUVER, BC–(Marketwired – October 27, 2017) – Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB)(XETRA: ZSB) announced today the resignation of Mr. David Moore from the board of directors due to conflicting commitments.
“We are very thankful to Mr. Moore for his contributions and guidance during his time on our board and wish him much success in his new position,” said Dr. Howard Verrico, CEO. “At this time the Company will remain with a vacancy on the board until a suitable replacement is found.”
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
For more information regarding this press release, contact:
Christopher Hopton, CFO
Sirona Biochem Corp.
Phone: 1.604.282.6064
Email: chopton@sironabiochem.com
- Published in Bio technology, Life Sciences, News Home, Sirona Biochem
Sirona Biochem Announces Close of Oversubscribed Private Placement
Momentum Public Relations
Press Release: October 26, 2017
VANCOUVER, BC–(Marketwired – October 26, 2017) – Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB)(XETRA: ZSB) (the “Company“) announced today that it has closed an oversubscribed, non-brokered private placement for gross proceeds of $635,000. The private placement consists of 4,233,333 units, (the “Units”) at a price of $0.15 per Unit. Each Unit consists of one common share and one transferable share purchase warrant, each whole warrant exercisable into one additional common share of the Company for a period of 2 years from the date of issue at a price of $0.25 per share.
Dr. Howard Verrico, CEO, has participated in the Private Placement with the purchase of 1,000,000 Units and upon completion, owns 5,951,250 common shares.
All securities issued under the placement are subject to statutory hold periods expiring on February 26, 2018.
Proceeds of the placement will be used for general working capital.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
For more information regarding this press release, please contact:
Christopher Hopton
CFO
Sirona Biochem Corp.
Phone: 1.604.282.6064
Email: chopton@sironabiochem.com
- Published in Bio technology, News Home, Sirona Biochem
Sirona Biochem Announces Financing
Momentum Public Relations
Press Release: October 24, 2017
VANCOUVER, BC–(Marketwired – October 24, 2017) – Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB)(XETRA: ZSB) (the “Company“) announced today that it has arranged a non-brokered private placement for gross proceeds of $535,000. The private placement consists of 3,566,667 units, (the “Units”) at a price of $0.15 per Unit. Each Unit consists of one common share and one transferable share purchase warrant, each whole warrant exercisable into one additional common share of the Company for a period of 2 years from the date of issue at a price of $0.25 per share.
Proceeds of the placement will be used for general working capital.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
For more information regarding this press release, please contact:
Christopher Hopton
CFO
Sirona Biochem Corp.
Phone: 1.604.282.6064
Email: chopton@sironabiochem.com
- Published in Bio technology, News Home, Sirona Biochem
Sirona Biochem to Present Kel-01 at Cosmetic 360 in Paris, France
Momentum Public Relations
Press Release: October 16, 2017
VANCOUVER, BC–(Marketwired – October 16, 2017) – Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB)(XETRA: ZSB), (the “Company”) announced that Chief Scientific Officer, Dr. Geraldine Deliencourt-Godefroy, will attend and present on the trade floor at Cosmetic 360 in Paris, France on October 18-19, 2017. Cosmetic 360 is an international event that brings together the leading advancements in science with the largest, most influential cosmetics companies. In 2016, the conference hosted 200 exhibitors and was attended by over 4,000 delegates.
At the conference, Sirona will exhibit a trade show booth to academics and industry alike on the Company’s proprietary compound Kel-01. Kel-01 is currently being developed to prevent or reduce keloid scars. Initial studies have shown that the addition of KEL-01 regulates collagen I/III ratios in keloid fibroblasts to those of normal fibroblasts. Moreover, it also enhances the cellular antioxidant capacity through activation of the Nrf2 pathway.
Keloid scars are overgrown, hard tissue that extend outside the original area of skin damage. These scars affect approximately 10-15{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} of all wounds and current treatments are extremely limited. The global scar treatment market is poised to rise at a CAGR of 10.3{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} to over US$ 31.9 Billion by 2022 (Source: Persistence Market Research). Some of the key players in the keloid treatment market are Novartis, GlaxoSmithKline, Bristol-Myers Squibb and Valeant Pharmaceuticals International.
About Cosmetic 360
Cosmetic 360 is an innovative-centered trade fair for the cosmetic industry. The conference brings together professionals and industry representatives from all over the world. All facets of the cosmetic industry are represented at the conference including raw materials, formulation, packaging, testing and analysis, finished products, and distribution. More information on the conference can be found at https://www.cosmetic-360.com/en/
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
For more information regarding this press release, contact:
Christopher Hopton
CFO
Sirona Biochem Corp.
Phone: 1.604.282.6064
Email: chopton@sironabiochem.com
- Published in Bio technology, News Home, Sirona Biochem
Sirona Subsidiary, TFChem, Receives Final Loan Tranche from French Public Investment Bank for Anti-Aging Project
Momentum Public Relations
Press Release: September 27, 2017
VANCOUVER, BC–(Marketwired – September 27, 2017) – Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB), (the “Company”) announced that its wholly-owned French subsidiary, TFChem, has received the final tranche of the CDN$1.2 million from Bpifrance (the French Public Investment Bank) and the district of Haute Normandie. The final loan tranche, totaling CDN$487,000, will be used to advance the organization’s anti-aging project.
Repayment of the loan will be made in installments, beginning in Q3 2018 with the majority being paid after 2020. The company expects to be well into substantial milestone and royalty payments before any repayment of the loan begins.
According to the latest report by Zion Market Research, the global anti-aging market is expected to reach USD 216.52 billion in 2021 and is anticipated to grow at a CAGR of 7.5{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} between 2016 and 2021.
“The final loan tranche will be used to further the studies for anti-aging activity and mechanism of action of the glycoprotein library compounds,” reports Dr. Howard Verrico, CEO and Chairman of Sirona Biochem, “We would like to extend our gratitude to Bpifrance and the district of Haute Normandie.”
About Sirona’s Cell Preservation / Anti-Aging Project
TFChem has developed a library of novel glycopeptides with a unique ability to protect skin fibroblasts from severe stressors that arise from the natural aging process and the environment. Studies have shown that cells coated in these glycopeptides, even when exposed to oxidation, starvation and UV irradiation, maintain vitality under the stressors.
While the compounds have undergone several rounds of testing for activity, they require further assessment to determine a mechanism of action. The library is also being evaluated for effectiveness in preserving other cell types, expanding market opportunity. Potential commercial opportunities could include cell storage, transplant and healing.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
For more information regarding this press release, contact:
Christopher Hopton
CFO
Sirona Biochem Corp.
Phone: 1.604.282.6064
Email: chopton@sironabiochem.com
- Published in Bio technology, Life Sciences, News Home, Sirona Biochem, Technology